Evidence map›Paper›PMID 40401651›Full record

ReviewCardiology journal2025

Extended dual antithrombotic therapy in patients with chronic coronary syndrome - which agent should be added to aspirin?

Jacek Kubica, Piotr Adamski, Katarzyna Buszko, Piotr Buszman, Nader Elmasri, Tomasz Fabiszak, Jakub Foryś, Robert Gajda, Mariusz Gąsior, Robert Gil and 31 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors.

Jacek KubicaCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Piotr AdamskiCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Katarzyna BuszkoCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Piotr BuszmanCentre for Cardiovascular Research and Development of American Heart of Poland, Katowice, Gruppo San Donato, Katowice Poland.
Nader ElmasriAmerican Heart of Poland, Sztum, Poland.
Tomasz FabiszakCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Jakub ForyśAmerican Heart of Poland, Zgierz, Poland.
Robert GajdaModern Medical Technologies Center, Torun, Poland.
Mariusz Gąsior3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland.
Robert GilDepartment of Cardiology, National Institute of Medicine Ministry of the Internal Affairs and Administration, Warsaw, Poland.
Paweł GrzelakowskiDepartment of Cardiology and Cardiac Surgery, 10th Military Hospital and Polyclinic, Bydgoszcz, Poland.
Tomasz HajdukiewiczDepartment of Cardiology, Provincial Hospital of Elblag, Poland.
Miłosz Jaguszewski1st Department of Cardiology, Medical University of Gdansk, Gdansk, Poland.
Adam KernDepartment of Cardiology and Internal Medicine, University of Warmia and Mazury in Olsztyn, Poland.
Wacław KochmannDepartment of Cardiovascular Disease, Centre of Postgraduate Medical Education, Warsaw, Poland.
Jacek KonarskiAmerican Heart of Poland, Pila, Poland.
Aldona KubicaCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Tobiasz KudlaAmerican Heart of Poland, Kedzierzyn-Kozle, Poland.
Wiktor KuliczkowskiClinical Department of Cardiology, Department of Cardiology, Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University.
Aleksandra Kusińska-CzyczyłoAmerican Heart of Poland, Kedzierzyn-Kozle, Poland.
Ewa LaskowskaCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Przemysław MagielskiScientia Research Institute, Bydgoszcz, Poland.
Piotr MichalskiCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Krzysztof MilewskiAmerican Heart of Poland, Bielsko-Biala, Poland.
Natalia MrzywkaAmerican Heart of Poland, Pila, Poland.
Piotr NiezgodaCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. piotr.niezgoda1986@gmail.com.ORCID 0000-0002-9912-9730
Małgorzata OstrowskaCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Maciej PiaseckiCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Przemysław PodhajskiCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Janusz ProkopczukAmerican Heart of Poland, Kedzierzyn-Kozle, Poland.
Jakub RatajczakCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Alicja Rzepka-CholasińskaCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Grzegorz SkoniecznyClinical Department of Cardiology, The Ludwik Rydygier Provincial Polyclinical Hospital, Torun, Poland.
Giuseppe SpecchiaProfesor emeritus, Department of Cardiology, University of Pavia, Italy.
Łukasz SzarpakDepartment of Clinical Research and Development, LUXMED Group, Warsaw, Poland.
Paweł SzymańskiRegional Specialistic Hospital, Grudziadz, Poland.
Małgorzata TopolskaAmerican Heart of Poland, Katowice, Poland.
Julia M UmińskaCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Marcin ZiółkowskiCollegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Aleksander ŻurakowskiAndrzej Frycz Modrzewski Krakow University, Poland.
Eliano Pio NavareseClinical Experimental Cardiology, Clinical and Interventional Cardiology, University of Sassari, Sassari, Sardinia Island, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

According to the 2024ESC Guidelines for the management of chronic coronary syndromes dual antithrombotic treatment comprising aspirin and a second antithrombotic drug for extended long-term prevention should be considered in patients at increased ischemic risk without high bleeding risk. However, no clear indications regarding the choice of a second antithrombotic agent are provided. It was therefore decided to discuss the available evidence regarding this issue. The guidelines provided the number needed to treat (NNT) and the number needed to harm (NNH) for each proposed medication. However, the presented data are misleading and may result in unjustified therapeutic decisions. Due to the great impact of this document on clinical practice all data provided in this document should be carefully verified and commented regarding limitations.

Indexed as

AspirinFibrinolytic AgentsPlatelet Aggregation InhibitorsChronic DiseaseDrug Therapy, CombinationHemorrhageHumansPractice Guidelines as TopicRisk FactorsTreatment OutcomeAspirinFibrinolytic AgentsPlatelet Aggregation Inhibitorschronic coronary syndromeclopidogrelextended antithrombotic therapyprasugrelrivaroxabanticagrelor

Identifiers

PMID40401651
PMCPMC12221334

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.